Australian Gonococcal Surveillance Program, 1 April to 30 June 2023

Authors

  • Monica M Lahra World Health Organization Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, NSW Health Pathology Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW 2052, Australia
  • Sebastiaan Van Hal Molecular Microbiology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
  • Tiffany R Hogan World Health Organization Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, NSW Health Pathology Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia

DOI:

https://doi.org/10.33321/cdi.2024.48.13

Keywords:

antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeae

Abstract

The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on sensitivity to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data for the indicated quarter.

Downloads

Download data is not yet available.

References

World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2012. Available from: https://apps.who.int/iris/handle/10665/44863.

van Hal SJ, Whiley DM, Le T, Ray S, Kundu RL, Kerr E et al. Rapid expansion of Neisseria gonorrhoeae ST7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype. J Antimicrob Chemother. 2023;78(9):2203–8. doi: https://doi.org/10.1093/jac/dkad221.

Lahra MM, van Hal S, Hogan TR. Australian Gonococcal Surveillance Programme, 1 January to 31 March 2023. Commun Dis Intell (2018). 2023;48. http://doi.org/10.3321/cdi.2024.48.12.

Lahra MM, van Hal S, Hogan TR. Australian Gonococcal Surveillance Programme Annual Report, 2022. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.45.

Ouk V, Pham CD, Wi T, van Hal SJ, Lahra MM, EGASP Cambodia working group. The Enhanced Gonococcal Surveillance Programme, Cambodia. Lancet Infect Dis. 2023;23(9):e332–3. doi: https://doi.org/10.1016/S1473-3099(23)00479-6.

Day M, Pitt R, Mody N, Saunders J, Rai R, Nori A et al. Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. Euro Surveill. 2022;27(46):2200803. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.46.2200803.

Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S et al. Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Euro Surveill. 2022;27(24):2200455. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.24.2200455.

Berçot B, Caméléna F, Mérimèche M, Jacobsson S, Sbaa G, Mainardis M et al. Ceftriaxone-resistant, multidrug-resistant Neisseria gonorrhoeae with a novel mosaic penA-237.001 gene, France, June 2022. Euro Surveill. 2022;27(50):2200899. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.50.2200899.

Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364. doi: https://doi.org/10.1186/s12879-015-1029-2.

Downloads

Published

28/03/24

How to Cite

Lahra, Monica M, Sebastiaan Van Hal, and Tiffany R Hogan. 2024. “Australian Gonococcal Surveillance Program, 1 April to 30 June 2023”. Communicable Diseases Intelligence 48 (March). https://doi.org/10.33321/cdi.2024.48.13.

Issue

Vol. 48 (2024)

Section

Quarterly report

Categories

License

Copyright (c) 2024 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 9 10 > >>